The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward? Guests: <ul><li>Tay Salimullah, Chief Access Commercial Officer at Novartis</li><li>Jason Jones, Global Business Development Lead at Cellular Origins</li></ul>

<description>&lt;p&gt;&lt;span style="background-color: transparent;"&gt;The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward?&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;strong style="background-color: transparent;"&gt;Guests:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;span style="background-color: transparent;"&gt;Tay Salimullah, Chief Access Commercial Officer at Novartis&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style="background-color: transparent;"&gt;Jason Jones, Global Business Development Lead at Cellular Origins&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;</description>

The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ...

Invent: Life Sciences

Part One: Why Do We Need to Continue Innovating in the CGT Industry?

Part One: Why Do We Need to Continue Innovating in the CGT Industry?

Description